MEP39308A - Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method - Google Patents

Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method

Info

Publication number
MEP39308A
MEP39308A MEP-393/08A MEP39308A MEP39308A ME P39308 A MEP39308 A ME P39308A ME P39308 A MEP39308 A ME P39308A ME P39308 A MEP39308 A ME P39308A
Authority
ME
Montenegro
Prior art keywords
substance
subcutaneous dose
fsh
substances
amount equivalent
Prior art date
Application number
MEP-393/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Evert Johannes Bunschoten
Bennink Herman Jan Tijmen Coelingh
Original Assignee
Ares Trading S A Chateau De Vaumarcus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading S A Chateau De Vaumarcus filed Critical Ares Trading S A Chateau De Vaumarcus
Publication of MEP39308A publication Critical patent/MEP39308A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-393/08A 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method MEP39308A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077221 2002-06-07
PCT/NL2003/000370 WO2003103770A2 (en) 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method

Publications (1)

Publication Number Publication Date
MEP39308A true MEP39308A (en) 2011-02-10

Family

ID=29724462

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-393/08A MEP39308A (en) 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method

Country Status (21)

Country Link
US (1) US7815912B2 (ru)
EP (1) EP1511537B1 (ru)
JP (1) JP2005530818A (ru)
KR (1) KR20050058285A (ru)
CN (1) CN1684737A (ru)
AU (1) AU2003274929B2 (ru)
BR (1) BR0305033A (ru)
CA (1) CA2488719A1 (ru)
EA (1) EA009371B1 (ru)
ES (1) ES2399962T3 (ru)
IL (1) IL165522A0 (ru)
IS (1) IS7586A (ru)
ME (1) MEP39308A (ru)
MX (1) MXPA04012246A (ru)
NO (1) NO20045304L (ru)
NZ (1) NZ536984A (ru)
PL (1) PL373991A1 (ru)
RS (1) RS105004A (ru)
UA (1) UA81251C2 (ru)
WO (1) WO2003103770A2 (ru)
ZA (1) ZA200409857B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114412B1 (en) * 2007-01-08 2010-07-14 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
RU2014103185A (ru) 2011-07-18 2015-08-27 Артс Байолоджикс А/С Биологически активное соединение на основе лютеинизирующего гормона (lh) с пролонгированным действием
US20150272622A1 (en) 2011-12-22 2015-10-01 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo
US9216037B2 (en) 2013-06-21 2015-12-22 Previvo Genetics, Llc Uterine lavage for embryo retrieval
US9282995B2 (en) * 2011-12-22 2016-03-15 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo
CA3031252A1 (en) 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
EP4025207A1 (en) 2019-09-03 2022-07-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
US20230102503A1 (en) 2020-02-10 2023-03-30 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0788799A3 (en) * 1996-02-07 1998-10-21 ASTA Medica Aktiengesellschaft LHRH-Antagonists in the treatment of fertility disorders
CN1199642A (zh) * 1997-05-16 1998-11-25 Asta药物股份公司 治疗不育症的lhrh－拮抗剂
ES2247710T3 (es) * 1997-06-20 2006-03-01 Akzo Nobel N.V. Antagonista de gonadotropina.
RU2221588C2 (ru) * 1998-04-23 2004-01-20 Центарис АГ Способ терапевтического лечения бесплодия
KR20010093280A (ko) * 1999-02-24 2001-10-27 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 불임증 치료
US20030092628A1 (en) * 1999-06-23 2003-05-15 De Greef Henrik Johan Matthieu Maria Gonadotropin releasing hormone antagonist
JP2003503358A (ja) * 1999-06-23 2003-01-28 アクゾ・ノベル・エヌ・ベー ゴナドトロピン放出ホルモンのアンタゴニスト
RS51505B (sr) * 2001-09-12 2011-06-30 Laboratoires Serono Sa. Korišćenje lh u kontrolisanoj hiperstimulaciji ovarijuma
EP1862182A2 (en) 2001-12-21 2007-12-05 Pantarhei Bioscience B.V. Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method

Also Published As

Publication number Publication date
EP1511537B1 (en) 2012-11-21
PL373991A1 (en) 2005-09-19
JP2005530818A (ja) 2005-10-13
US7815912B2 (en) 2010-10-19
ES2399962T3 (es) 2013-04-04
RS105004A (en) 2007-02-05
EA009371B1 (ru) 2007-12-28
WO2003103770A2 (en) 2003-12-18
MXPA04012246A (es) 2005-04-08
UA81251C2 (en) 2007-12-25
CN1684737A (zh) 2005-10-19
IL165522A0 (en) 2006-01-15
EP1511537A2 (en) 2005-03-09
KR20050058285A (ko) 2005-06-16
NO20045304L (no) 2005-02-07
US20050235374A1 (en) 2005-10-20
NZ536984A (en) 2008-01-31
IS7586A (is) 2004-12-03
AU2003274929A1 (en) 2003-12-22
AU2003274929B2 (en) 2008-04-10
CA2488719A1 (en) 2003-12-18
BR0305033A (pt) 2004-11-09
ZA200409857B (en) 2006-02-22
EA200401619A1 (ru) 2005-06-30
WO2003103770A3 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
Schneider et al. Estradiol and the neuroendocrine control of LH release in vitro
Emons et al. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines
AR011217A1 (es) UN PÉPTIDO ANTAGONISTA DE GNRH, UNA COMPOSICIoN FARMACÉUTICA PARA INHIBIR LA SECRECIoN DE GONADOTROPINAS EN MAMíFEROS Y UN COMPUESTO INTERMEDIARIO PARA PREPARAR UN PÉPTIDO ANTAGONISTA DE GNRH.
Huirne et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study
MEP39308A (en) Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
ROSEMBERG et al. Clinical effect of human urinary postmenopausal gonadotropin
RU2005136527A (ru) Унитарная комбинация fsh и hcg
KR950703359A (ko) 임신치료를 위한 파라소면(parathormone), 그 생물학적 활성 프래그먼트(fragment) 및 관련 펩티드(peptide)의 용도
Reichman et al. GnRH antagonist-based protocols for in vitro fertilization
Tur-Kaspa et al. GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology
EA200200801A1 (ru) Применение фолликулостимулирующего гормона (fsh) для лечения бесплодия
EA200400591A1 (ru) СПОСОБ ВВЕДЕНИЯ ПЕПТИДА ТИМОЗИН α1
WO2005018657A3 (en) NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
AU631660B2 (en) A process for treating infertility and an agent for use in the process
WO2005019457A3 (en) NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
Mills et al. Is the postovulatory release of follicle-stimulating hormone in the rabbit mediated by luteinizing hormone-releasing hormone?
YU81203A (sh) Pojedinačna doza inhibitora aromataze za lečenje neplodnosti
KR20030051828A (ko) 에스트로겐 의존성 질환의 병용 치료법
Malven et al. A mechanism antagonizing the luteotrophic action of exogenous prolactin in rats
Curry Alterations in incidence of mating and copulation-induced ovulation after olfactory bulb ablation in female rats
BR9611760A (pt) Novos antagonistas lh-rh com efeito aperfeiçoado
Bretzlaff Physiology and pharmacology of the postpartum cow and retained fetal membranes
Torres et al. Comparison of embryo implantation in Wistar rats that underwent ovarian stimulation using exogenous gonadotropins associated with cetrorelix acetate or leuprolide acetate
Tarhan et al. Oxytocin-induced contractions of the rabbit corpus cavernosum
Felberbaum et al. Entwicklung und Anwendung der GnRH-Analoga in der Sterilitätstherapie